Furthermore, animal experiments have shown that HSC activation is often accompanied by an increase in the level of TGF-β1 and that inhibition of TGF-β1 synthesis, as well as TGF-β receptor blockade, can significantly reduce the pressure of portal hypertension [55]. Here, TGFB1 is linked to liver disorder.